SecBot SecBot
SECBOTREPLAY Home › Report › QTTB

QTTB · Q32 Bio Inc

Q32 Bio Inc. · 424B5 filed Mar 27, 2026 at 17:13 ET

At the news

BEARISHIMPACT 6/10

424B5 filed Mar 27, 2026 at 17:13 ET

Q32 Bio Inc. (QTTB) has filed a 424B5 prospectus supplement to register the at-the-market offering of up to $14.2 million in common stock through Cantor Fitzgerald. The offering allows the company to sell shares from time to time at prevailing market prices, with Cantor earning a 3% commission on sales. The company intends to use the proceeds for working capital and advancing its lead drug candidate, bempikibart, into future clinical trials for alopecia areata.

  • Q32 Bio is offering up to $14,200,000 in common stock through an at-the-market offering via Cantor Fitzgerald
  • The offering has no minimum amount and will be sold at prevailing market prices, with Cantor earning a 3% commission
  • Proceeds will be used for working capital and advancing bempikibart into future clinical trials for alopecia areata
  • The company has a market cap of $104M and the public float is approximately $74.2M

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access